Histogenics Corporation (HSGX) and Catalent (CTLT) Critical Analysis
Histogenics Corporation (NASDAQ: HSGX) and Catalent (NASDAQ:CTLT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.
Earnings and Valuation
This table compares Histogenics Corporation and Catalent’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Histogenics Corporation||N/A||N/A||-$25.96 million||($1.85)||-1.11|
|Catalent||$2.08 billion||2.54||$407.50 million||N/A||N/A|
Catalent has higher revenue and earnings than Histogenics Corporation.
This is a breakdown of current ratings and target prices for Histogenics Corporation and Catalent, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Histogenics Corporation currently has a consensus target price of $4.00, indicating a potential upside of 95.12%. Catalent has a consensus target price of $38.60, indicating a potential downside of 8.60%. Given Histogenics Corporation’s stronger consensus rating and higher possible upside, research analysts clearly believe Histogenics Corporation is more favorable than Catalent.
This table compares Histogenics Corporation and Catalent’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
50.1% of Histogenics Corporation shares are held by institutional investors. 23.8% of Histogenics Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Catalent beats Histogenics Corporation on 6 of the 10 factors compared between the two stocks.
About Histogenics Corporation
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Receive News & Stock Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related stocks with our FREE daily email newsletter.